News for Nuvalent, Inc. (NUVL)

On February 18, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring 5,825,000 shares of Solid Biosciences Inc (NASDAQ: SLDB) at

On February 19, 2025, Bain Capital Life Sciences Investors, LLC (Trades, Portfolio) made a significant move by acquiring an additional 1,000,000 shares in Solid

On February 19, 2025, Perceptive Advisors LLC made a significant move by acquiring an additional 5,028,033 shares of Solid Biosciences Inc (SLDB). This transact

Overview of the Recent Transaction On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a significant transaction involving Applied Therap

On December 31, 2024, Perceptive Advisors LLC made a significant move by reducing its stake in Amicus Therapeutics Inc (FOLD). The firm decreased its holdings b

Transaction Overview On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a notable transaction by acquiring an additional 5,509,236 share

On February 5, 2025, Paradigm Biocapital Advisors LP (Trades, Portfolio) made a significant move by acquiring an additional 950,162 shares of Cogent Biosciences

On December 31, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) made a significant move by acquiring an additional 136,463 shares of Elutia Inc, a c

On December 31, 2024, Vanguard Group Inc executed a noteworthy transaction by acquiring additional shares in Nuvalent Inc. The firm added 366,239 shares of Nuva

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Read the full report on the stock here.

Nuvalent Inc (NUVL), a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, announced its strategic milestones for 2025, aiming for its f

PR NewswireCAMBRIDGE, Mass., Jan. 13, 2025 Strategy prioritizes most accelerated path to first potential approval Initial NDA submission expected by mid-ye

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC, with impressive Phase I/II trial results. Read my NUVL thesis.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

PR NewswireCAMBRIDGE, Mass., Dec. 9, 2024 CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday. The Dow traded up 0.29% to 41,512.19 while the NASDAQ f...

The increase in the prevalence of Non-Small Cell Lung Cancer (NSCLC) drives market growth by boosting demand for innovative treatments, and personalized...

MGP Ingredients faces challenges in revenue, competition, and debt, limiting growth prospects. See why we are on the sidelines for MGPI stock.

Revolution is pioneering a unique precision-based approach to developing oncology drugs that target the RAS pathway. Read why I'm neutral on RVMD stock.